Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 236 of 5804
-
Could a One-Time treatment give kidney cancer patients a year off drugs?
Disease control Not yet recruitingThis is a non-randomized, open-label phase II study designed to estimate 12-month treatment-free survival rate following total consolidative metastasis-and-primary directed therapy (MPDT) among patients with partial response/stable disease after at least 6 months of immune checkp…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo targets ALS inflammation in genetically selected patients
Disease control Not yet recruitingAmyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality. A growing body of translational and clinical evidence impl…
Phase: PHASE2, PHASE3 • Sponsor: Gipfel Life Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Choice of location may boost HIV prevention persistence
Prevention Not yet recruitingPrEP4U is designed as a pragmatic, randomized implementation trial to test strategies that could directly inform real-world roll-out of lenacapavir. By integrating: * Same-day initiation based on rapid HIV testing, and * Choice of follow-up delivery location (home, community, or…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to boost CAR-T success in hard-to-treat lymphoma
Disease control Recruiting nowThe purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for rare leukemia: drug cocktail shows promise
Disease control Not yet recruitingAcute leukemia of ambiguous lineage (ALAL), which refers to acute leukemia without definite evidence indicating cell differentiation along a specific lineage, mainly encompasses two major categories: acute undifferentiated leukemia (AUL) lacking the expression of lineage-specific…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a Weight-Loss drug ease rett syndrome?
Symptom relief Not yet recruitingThe purpose of this study is to investigate the efficacy of fenfluramine hydrochloride (HCl) versus placebo in study participants with Rett syndrome (RTT).
Phase: PHASE3 • Sponsor: UCB BIOSCIENCES, Inc. • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
New hope for cancer patients: experimental drug aims to stop dangerous blood clots
Disease control Recruiting nowThis study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \[DVT\]) that blo…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill takes on Hard-to-Treat KRAS cancers
Disease control Recruiting nowA first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
Phase: PHASE1, PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Mind-Reading chip aims to give voice to the speechless
Disease control Not yet recruitingThis prospective, single-arm clinical trial is designed to preliminarily evaluate the safety and efficacy of an implantable wireless brain-computer interface (BCI) system (manufactured by Shanghai StairMed Technology Co., Ltd.) in enabling subjects with speech disorders to achiev…
Phase: NA • Sponsor: Shanghai StairMed Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
Disease control Not yet recruitingThe goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB…
Phase: PHASE1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Radiation may tame Treatment-Resistant breast cancer
Disease control Not yet recruitingFor locally advanced or recurrent metastatic breast cancer that is resistant to systemic therapy, radiotherapy (RT) may be considered as the preferred treatment option when the lesion is unresectable, or the patient is not suitable for surgery. This study aim to evelatuate the lo…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Inhaled drug could offer new hope for lung scarring disease
Disease control Recruiting nowThis trial is a randomized, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of inhaled Nintedanib Dry Powder Inhalation (DPI) in adults with idiopathic pulmonary fibrosis (IPF). Participants are randomized to receive either 2 mg QID, 4 mg BID…
Phase: PHASE2 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug duo takes on recurrent brain cancer
Disease control Recruiting nowThe primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.
Phase: PHASE2 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo attack on untreatable liver cancer shows promise in early trial
Disease control Not yet recruitingPurpose: This phase II clinical trial evaluates whether a combination of liver-directed local therapies (HAIC and DEB-TACE) with immunotherapy (toripalimab) and targeted therapy (lenvatinib) is safe and effective for patients with unresectable intrahepatic cholangiocarcinoma (a t…
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Heart attack patients may get a powerful new tool to slash cholesterol
Disease control Not yet recruitingThis study aims to evaluate the effectiveness and safety of implementing a systematic augmented low-density lipoprotein cholesterol (LDL-C) management care pathway initiated in hospitals for patients with Acute Coronary Syndrome. This pathway includes treatment with inclisiran on…
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
A simple breath test could spot lung infections in minutes
Diagnosis Not yet recruitingLower respiratory tract infections (LRTIs) remain a major global health burden, with diagnosis often challenged by clinical heterogeneity, overlapping symptoms, difficulty in obtaining quality biological specimens and limitations of conventional microbiological testing. Exhaled b…
Phase: NA • Sponsor: Hopital Foch • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
Three-Drug cocktail aims to shrink breast tumors before surgery
Disease control Not yet recruitingThis study is a single-center, prospective, open-label exploratory clinical study to assess the efficacy and safety of kumorixilib combined with capecitabine and letrozole as neoadjuvant therapy in patients with HR+/HER2- stage II-III invasive breast cancer. The study plans to en…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New antibiotic lefamulin takes on Drug-Resistant pneumonia
Disease control Not yet recruitingCommunity-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually. Elderly CAP patients carry a higher mortality risk. The predom…
Sponsor: Marubeni Pharmaceuticals (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Why some Never-Smokers get lung cancer: a new study investigates
Knowledge-focused Recruiting nowThe researchers are doing this study to learn more about factors that may increase the risk of lung cancer in people who have never smoked. This information may help predict which people who have never smoked may be more likely to get lung cancer.
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Can a Two-Pronged surgical approach beat standard surgery for neck pain?
Disease control Not yet recruitingThe objective of this clinical trial is to evaluate the treatment of patients with two-level cervical degenerative disease using a combination of Anterior Cervical Discectomy and Fusion (ACDF) and Posterior Cervical Fusion (PCF) procedures. The primary outcome measure is the rat…
Phase: NA • Sponsor: Providence Medical Technology, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC